![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
According to Bayer, Bayer has completed the acquisition of the Swiss Roche Group's public drug business. From January this year, Roche's public pharmaceutical business will become part of Bayer HealthCare's consumer products business. The European Commission approved Bayer's plan to acquire Roche's public pharmaceutical business years ago. As a condition of approval, the European Commission asked Bayer to divest its regional rights to three Roche products. The combined annual sales of these three products amounted to 2.25 million Euros, accounting for 0.23% of the sales for this acquisition. The transaction includes all the assets of the Roche Pharmaceuticals Division and five production sites in Germany, France, Argentina, Morocco and Indonesia. After the acquisition of the Roche Pharmaceuticals Division, Bayer's Public Health Department, which is one of the business units of Bayer Health, will rank among the top 3 in the global nonprescription business. The drugs of the two companies have high market share in Europe and the United States. After the acquisition is completed, Bayer's sales of non-prescription drugs will reach 2.4 billion euros. Bayer's CEO Arthur Higgins said that Bayer will create the world's leading non-prescription drug company through acquisitions that will integrate the two companies' over-the-counter drug production, R&D capabilities and established brand advantages.
DSJH-Type Petrochemical Process Pump
Petrochemical Process Pump,Centrifugal Petrochemical Pumps,Petrochemical Industry Pump
Shenyang pump products sales co., LTD , http://www.syipsc.com